Cargando…

A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma

Paclitaxel (P) and bevacizumab (B) are agents that provide clinical benefit in advanced angiosarcoma (AS). The objective of this study was to assess the efficacy and safety of P-B in two different scheduled regimens. Patients were to receive P 200mg/m2 IV with B 15mg/kg IV every 21 days (Regimen A)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bui, Nam, Kamat, Nikhil, Ravi, Vinod, Chawla, Sant, Lohman, Marti, Ganjoo, Kristen N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946584/ https://www.ncbi.nlm.nih.gov/pubmed/29760870 http://dx.doi.org/10.1177/2036361318771771

Ejemplares similares

Propranolol and Weekly Paclitaxel in the Treatment of Metastatic Heart Angiosarcoma
por: Fiste, Oraianthi, et al.
Publicado: (2020)

Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma
por: Apice, Gaetano, et al.
Publicado: (2016)

Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
por: Lebellec, Loïc, et al.
Publicado: (2018)

Management Strategies and Outcomes in Primary Liver Angiosarcoma
por: Ramakrishnan, Neeraj, et al.
Publicado: (2023)

Cutaneous Angiosarcoma of the Head and Neck—A Retrospective Analysis of 47 Patients
por: Ramakrishnan, Neeraj, et al.
Publicado: (2022)

A Korean single-center, real-world, retrospective study of first-line weekly paclitaxel in patients with metastatic angiosarcoma
por: Byeon, Seonggyu, et al.
Publicado: (2016)

Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma
por: Minichillo, Santino, et al.
Publicado: (2015)

Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
por: Calvo, Emiliano, et al.
Publicado: (2022)

Prospective results of concurrent radiation therapy and weekly paclitaxel as salvage therapy for unresectable locoregionally recurrent breast cancer
por: Cai, Gang, et al.
Publicado: (2019)

Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer
por: Redondo, Andrés, et al.
Publicado: (2014)

Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial
por: Jones, Robin L., et al.
Publicado: (2022)

Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study
por: Ardavanis, Alexandros, et al.
Publicado: (2009)

Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
por: Osman, Mohammed A., et al.
Publicado: (2016)

Severe skin toxicity due to weekly paclitaxel administration
por: Kate, Shruti, et al.
Publicado: (2015)

Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis
por: Landry, Kara K, et al.
Publicado: (2022)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel
por: Mendiola, Marta, et al.
Publicado: (2016)

Weekly vs. 3-weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
por: Geraghty, Leeann, et al.
Publicado: (2021)

A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial)
por: Koizumi, Wasaburo, et al.
Publicado: (2015)

Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor
por: Brar, Rondeep, et al.
Publicado: (2009)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer
por: Kim, Yoo-Na, et al.
Publicado: (2019)

Comparison of one-week versus three-week paclitaxel for advanced pan-carcinomas: systematic review and meta-analysis
por: Lin, Shitong, et al.
Publicado: (2022)

Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer
por: Shitara, K, et al.
Publicado: (2014)

Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?
por: Lee, Matilda X., et al.
Publicado: (2018)

Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma
por: Roy, Amit, et al.
Publicado: (2021)

Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group
por: Hirata, Kenro, et al.
Publicado: (2020)

Quasi-Complete Response of Classic Kaposi's Sarcoma Treated with Weekly Paclitaxel
por: Benbrahim, Zineb, et al.
Publicado: (2013)

Weekly paclitaxel as metronomic palliative chemotherapy in small cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2016)

A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer
por: Geara, Fady B, et al.
Publicado: (2010)

Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas
por: Testa, Stefano, et al.
Publicado: (2022)

Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors
por: Moding, Everett J., et al.
Publicado: (2017)

Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer
por: Cho, Sang-Hee, et al.
Publicado: (2005)

Pathologic Response After Weekly Paclitaxel versus Docetaxel in Operable Breast Cancer
por: Bacinschi, Xenia Elena, et al.
Publicado: (2020)

Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma
por: Wang, Hai-ying, et al.
Publicado: (2016)

Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression
por: Zhou, Maggie, et al.
Publicado: (2021)

Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer: A retrospective observational study
por: Oi, Hajime, et al.
Publicado: (2022)

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
por: Martín, Miguel, et al.
Publicado: (2013)

Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
por: Sun, Si, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_21qn0h7pan3cmphmvqta7inb09